Prognostic value of body composition and nutritional assessment in recurrent/metastatic squamous cell carcinoma of head and neck (R/M SCCHN) treated with immunotherapy (IO)

被引：0
|
作者：
Vidales Sepulveda, Z. [1 ]
Choulli, M. [2 ]
Fabrego, S. [2 ]
Pallares, N. [3 ]
Santos, N. [3 ]
Llop Serna, S. [1 ]
Brenes Castro, J. [1 ]
Plana Serrahima, M. [4 ]
Juarez Lozano, C. M. [5 ]
Brunet, A. [6 ]
Melero, M. [7 ]
Bermejo, O. [8 ]
Vilajosana, E. [1 ,9 ]
Godino, C. [10 ]
Oliva, M. [11 ]
Arribas, L. [12 ]
机构：
[1] ICO Inst Catala Oncol Hosp Hosp Duran I Reynals, Med Oncol Dept, Lhospitalet De Llobregat, Spain
[2] ICO Inst Catala Oncol Hosp Hosp Duran I Reynals, Nutr Dept, Lhospitalet De Llobregat, Spain
[3] IDIBELL Bellvitge Biomed Res Inst, Biostat Unit, Lhospitalet De Llobregat, Spain
[4] ICO Inst Catala Oncol Hosp Hosp Duran I Reynals, Med Oncol Dept, Barcelona, Spain
[5] Inst Catala Oncol Hosp Duran I Reynals ICO LHospi, Radiat Oncol, Barcelona, Spain
[6] Hosp Univ Bellvitge, Otolaryngol Dept, Lhospitalet De Llobregat, Spain
[7] Hosp Univ Bellvitge, Oral & Maxillofacial Surg Dept, Lhospitalet De Llobregat, Spain
[8] Hosp Univ Bellvitge, Plast Surg Dept, Lhospitalet De Llobregat, Spain
[9] ICO Inst Catala Oncol Hosp Hosp Duran I Reynals, Med Oncol Dept, Lhospitalet De Llobregat, Spain
[10] Inst Catala Oncol Hosp Duran I Reynals ICO LHospi, Med Oncol Dept, Barcelona, Spain
[11] Inst Catala Oncol Hosp Duran I Reynals ICO LHospi, Moliva Iconcol Net, Barcelona, Spain
[12] Inst Catala Oncol, Clin Nutr Unit, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2072
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
928P
引用
收藏
页码：S585 / S586
页数：2
相关论文
共 50 条
  • [21] Nutritional status (NS) as a strong predictor for immunotherapy (IT) outcome in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts)
    Hernando-Calvo, A.
    Mirallas, O.
    Marmolejo Castaneda, D. H.
    Vieito, M.
    Santa Gadea, O. Saavedra
    Gardeazabal, I.
    Villacampa Javierre, G.
    Aguilar, S.
    Martin Liberal, J.
    Bescos, C.
    Lorente, J.
    Giralt, J.
    Benavente, S.
    Fuentes, J. F.
    Temprana-Salvador, J.
    Alberola, M.
    Dienstmann, R.
    Garralda, E.
    Felip, E.
    Brana, I.
    ANNALS OF ONCOLOGY, 2020, 31 : S671 - S672
  • [22] Prognostic Value of Inflammatory and Nutritional Biomarkers of Immune Checkpoint Inhibitor Treatment for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
    Sakai, Akihiro
    Iijima, Hiroaki
    Ebisumoto, Koji
    Yamauchi, Mayu
    Teramura, Takanobu
    Yamazaki, Aritomo
    Watanabe, Takane
    Inagi, Toshihide
    Maki, Daisuke
    Okami, Kenji
    CANCERS, 2023, 15 (07)
  • [23] Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
    Borel, Christian
    Jung, Alain C.
    Burgy, Mickael
    CANCERS, 2020, 12 (09) : 1 - 19
  • [24] Correlates of Cetuximab Efficacy in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma Previously Treated With Immunotherapy
    Park, Jong Chul
    Ahn, Jong Seok
    Merkin, Ross
    Patel, Manisha
    Wirth, Lori
    Roberts, Thomas J.
    JCO PRECISION ONCOLOGY, 2025, 9
  • [25] TREATMENT PATTERNS IN RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF HEAD AND NECK (R/M SCCHN) POST PLATINUM-BASED THERAPY (PPBT) IN THE IMMUNO-ONCOLOGY (IO) ERA
    Radtchenko, J.
    Korytowsky, B.
    Abraham, P.
    Singh, P.
    Feinberg, B. A.
    VALUE IN HEALTH, 2018, 21 : S56 - S56
  • [26] Prognostic significance of metastatic sites in recurrent or metastatic squamous cell carcinoma of the head and neck
    Nishimura, Ari
    Yokota, Tomoya
    Iida, Yoshiyuki
    Kamijo, Tomoyuki
    Mukaigawa, Takashi
    Onozawa, Yusuke
    Todaka, Akiko
    Hamauchi, Satoshi
    Kawakami, Takeshi
    Shirasu, Hiromichi
    Onoe, Tsuyoshi
    Ogawa, Hirohumi
    Kawabata, Takanori
    Yasui, Hirofumi
    Onitsuka, Tetsuro
    ANNALS OF ONCOLOGY, 2021, 32 : S296 - S296
  • [27] Efficacy and safety of nivolumab for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in Asia: CheckMate 141 subgroup analysis
    Hasegawa, Y.
    Kiyota, N.
    Takahashi, S.
    Yokota, T.
    Yen, C-J.
    Iwae, S.
    Shimizu, Y.
    Hong, R-L.
    Goto, M.
    Namba, Y.
    Ferris, R. L.
    Monga, M.
    Lynch, M.
    Hagihara, S.
    Tahara, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [28] Weekly paclitaxel, carboplatin and cetuximab (PCE) combination followed by nivolumab for recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
    Takeshita, Naohiro
    Enokida, Tomohiro
    Okano, Susumu
    Fujisawa, Takao
    Wada, Akihisa
    Sato, Masanobu
    Tanaka, Hideki
    Tanaka, Nobukazu
    Onaga, Ryutaro
    Hoshi, Yuta
    Sakashita, Shingo
    Ishii, Genichiro
    Tahara, Makoto
    ORAL ONCOLOGY, 2023, 147
  • [29] The role of cetuximab maintenance after chemotherapy in patients with recurrent/metastatic squamous cell carcinoma of head and neck (R/M SCCHN): A retrospective analysis
    Wakasugi, T.
    Enokida, T.
    Nakanome, A.
    Yamazaki, T.
    Okano, S.
    Tahara, M.
    ANNALS OF ONCOLOGY, 2015, 26 : 95 - 95
  • [30] Retrospective analysis of the use of cetuximab (CTX) and paclitaxel (PTX) combination in recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
    Soria Rivas, Ainara
    Rodriguez Garrote, Mercedes
    Olmedo Garcia, Maria Eugenia
    Lopez, Maria
    Garrido Lopez, Pilar
    Carrato, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345